Summary
Leila Janani is a Research Fellow and Senior Clinical trials Statistician at Imperial Clinical Trials Unit (ICTU). Within ICTU, she is Deputy Head of Trial Methodology (StatsCI).
She joined the Imperial Clinical Trials Unit (ICTU) as a research fellow in January 2021. She is currently working on the TREAT trial – an interesting Bayesian non-inferiority trial to treat severe paediatric asthma and the COVBOOST – a trial to establish the reactogenicity and immunogenicity of booster vaccinations against SARS-CoV2. Her current methodological research focuses on using adaptive analysis for late-phase trials in critical care.
Leila is a member of the NIHR Statistics Working Group-Improving Statistical Literacy and also serves as a member of IDMCs.
Her research interests are in statistical methods to improve the design, analysis, and reporting of randomised clinical trials with a specific focus on:
-Designing flexible and adaptive clinical trials
-Using the Bayesian approach in the analysis of clinical trials
She completed a BSc in Statistics from Tabriz University, Iran, followed by an MSc and PhD in Biostatistics from Tehran University of Medical Science, the highest-ranked medical university in Iran. She also attended an MBA certificate program held by the Sharif University of Technology. She has over 12 years of experience in teaching, designing, developing protocols, conducting, monitoring, analysing, and reporting clinical trial studies.
Leila started working as an Assistant Professor of Biostatistics at the Iran University of Medical Sciences immediately after she obtained PhD degree in 2015, and after 4 years, she could promote to the Associate level. Additionally, she has worked as a Head of the Biostatistics Unit, Clinical Trial Center (CTC), Tehran University of Medical Sciences. CTC initiated the first private knowledge-based clinical research organisation (CRO) in Iran that works closely with the Iran FDA to enhance the standards of conducting industry-initiated clinical trials by providing functional services to the pharmaceutical and medical device industries.
Publications
Journals
Darabi P, Gharibzadeh S, Khalili D, et al., 2024, Optimizing cardiovascular disease mortality prediction: a super learner approach in the tehran lipid and glucose study., Bmc Med Inform Decis Mak, Vol:24
Gupta A, Whiteley WN, Godec T, et al., 2024, Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial, European Heart Journal, Vol:45, ISSN:0195-668X, Pages:1159-1169
Liu X, Munro APS, Wright A, et al., 2023, Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial, Journal of Infection, Vol:87, ISSN:0163-4453, Pages:18-26
Liu X, Munro APS, Feng S, et al., 2023, Corrigendum to “Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial” [J Infect 84(6) (2022) 795–813, 5511], Journal of Infection, Vol:86, ISSN:0163-4453, Pages:540-541
Conference
Blake C, Tajik R, Janani L, et al., 2023, Identification of barriers to recruitment in studies exploring treatments for sexually transmitted infections, BMJ PUBLISHING GROUP, Pages:A93-A94, ISSN:1368-4973